Archives for: ‘Kim O’Connell’
The Full Federal Court has confirmed that Sanofi-Aventis’ patent for the drug clopidogrel (brand name Plavix) is invalid and should be revoked. Subject to the question of whether Sanofi will seek a stay pending an application for leave to appeal to the High Court, the decision clears the way for Apotex and other companies to launch their own brands of clopidogrel, a drug designed to prevent platelet aggregation and blood clots, to compete directly with Sanofi.
IP Australia has announced that requests for examination of patents involving green technology may be “fast-tracked”.
Uncertainty has arisen in the podcasting arena after VoloMedia, Inc, a company based in Sunnyvale, California, announced that it had been granted the “US Patent for Podcasting” at the end of July this year.
In the days following the announcement, two key questions emerged: can this patent be valid, and if so, how does VoloMedia intend to assert its newly acquired patent rights?
Advisory Council on Intellectual Property releases Interim Report on Post-Grant Patent Enforcement Strategies
The Advisory Council on Intellectual Property has released an Interim Report on Post-Grant Enforcement Strategies proposing a number of reforms, including the establishment of an IP dispute resolution centre to provide opinions in relation to validity and infringement issues, and public access to information in relation to patent related Court proceedings. The Advisory Council is seeking submissions on the proposals outlined in the Report from interested parties with a view to submitting the final report to the Government in late 2009. Written submissions should be mad